Coherus Biosciences, INC Form 4 insider transactions
NASDAQ
Coherus BioSciences' Chief Financial Officer, Bryan J. McMichael, was granted stock options for 160,000 shares on January 3, 2025.
NASDAQ
Form 4: Coherus BioSciences Executive Acquires Stock Options and Disposes of Shares for Tax Obligations
Paul Reider, Chief Commercial Officer of Coherus BioSciences, acquired 160,000 stock options and disposed of 2,277 shares to cover tax liabilities.
NASDAQ
Paul Reider, Chief Commercial Officer of Coherus BioSciences, reports the withholding of 2,073 shares for tax obligations related to vesting restricted stock units.
NASDAQ
Bryan J. McMichael, CFO of Coherus BioSciences, acquired 75,000 stock options at an exercise price of $1.24 on August 7, 2024.
NASDAQ
Coherus BioSciences CEO Dennis M. Lanfear acquired 196,500 shares of common stock through the vesting of a performance stock option following the closing of the YUSIMRY franchise sale.
NASDAQ
Paul Reider, Chief Commercial Officer of Coherus BioSciences, acquired stock options as part of a performance-based grant following the closing of the YUSIMRY franchise sale.
NASDAQ
Rita A. Karachun, a director of Coherus BioSciences, acquired stock options for 168,000 shares on June 4, 2024, at an exercise price of $1.78.
NASDAQ
Georgia Erbez, a director at Coherus BioSciences, acquired stock options for 114,000 shares on June 4, 2024.
NASDAQ
Charles W. Newton, a director at Coherus BioSciences, acquired stock options for 112,000 shares on June 3, 2024.
NASDAQ
Michael Lee Ryan, a director at Coherus BioSciences, acquired stock options for 112,000 shares on June 3, 2024.
NASDAQ
Mats Wahlstrom, a director at Coherus BioSciences, acquired stock options for 112,000 shares on June 3, 2024.
NASDAQ
Mark Stolper, a director at Coherus BioSciences, acquired 112,000 stock options on June 3, 2024, exercisable after one year.
NASDAQ
Director Lee Nisley Newcomer acquired stock options for 112,000 shares of Coherus BioSciences on June 3, 2024.
NASDAQ
Kimberly Jo Tzoumakas, a director at Coherus BioSciences, acquired stock options for 112,000 shares on June 3, 2024.
NASDAQ
Director Jill O'Donnell-Tormey acquired stock options for 112,000 shares of Coherus BioSciences common stock on June 3, 2024.